An innovative medicinal product can be a new active substance acting against or preventing a disease and developed to improve the quality of patient management and outcomes.
Thus, product novelty alone (in terms of chemical structure or mechanism of action) is not sufficient to characterize therapeutic innovation, as an improvement of health outcomes is necessary.
Recognizing a true innovation can accelerate the development and adoption of valuable treatment options, encouraging their prioritization to make them quickly available for patients with high un-met (or inadequately met) medical needs.
The field of ocular pharmacology has rapidly grown over the last few years, leading to the discovery and approval of disease modifying treatments for several untreatable eye disorders. Nevertheless, several unmet needs remain, in the areas of retinal dystrophies, glaucoma, diabetic retinopathy, and corneal diseases.
This Research Topic would like to collect updated evidence about true innovation for ocular diseases which still represent unmet medical needs, characterized by a devastating impact on the quality of life of patients but also on the healthcare system and the society. In particular, it will be focused on the current state and future perspectives in the area of innovation in ocular pharmacology, including treatments which have already demonstrated to generate improvements in patient outcomes that were previously unattainable, but also experimental products which would potentially represent disease modifying therapies. In this context, for instance manuscripts focused on advanced therapy medicinal products (ATMPs) are welcome; indeed, ATMPs, for example gene therapies, are changing the landscape of therapy for ocular diseases aiming to reverse and/or prevent blindness in patients with rare genetic disorders but also with chronic degenerative damages. As regard to products already on the market, evidence from real-world data will be acceptable, including commentaries about access to innovation.
This topic aims to look at innovative treatments but is not limited to the topic of advanced therapies. The Topic welcomes submissions of Original Research, Reviews, Clinical trials, Perspective, Policy Brief, Opinion articles that cover the following topics, but not limited to:
• Real-world data related to the use of products for ocular diseases recognized as real innovation already available in clinical practice (including gene therapies, novel formulations, biologics etc.);
• Access to innovation in specific national contexts (reimbursement, risk-sharing agreements, cost);
• Investigation on potential innovative pharmacological treatments for unmet medical needs (retinal dystrophies, glaucoma, diabetic retinopathy, age related macular degeneration);
• Innovative ocular drug delivery systems.
An innovative medicinal product can be a new active substance acting against or preventing a disease and developed to improve the quality of patient management and outcomes.
Thus, product novelty alone (in terms of chemical structure or mechanism of action) is not sufficient to characterize therapeutic innovation, as an improvement of health outcomes is necessary.
Recognizing a true innovation can accelerate the development and adoption of valuable treatment options, encouraging their prioritization to make them quickly available for patients with high un-met (or inadequately met) medical needs.
The field of ocular pharmacology has rapidly grown over the last few years, leading to the discovery and approval of disease modifying treatments for several untreatable eye disorders. Nevertheless, several unmet needs remain, in the areas of retinal dystrophies, glaucoma, diabetic retinopathy, and corneal diseases.
This Research Topic would like to collect updated evidence about true innovation for ocular diseases which still represent unmet medical needs, characterized by a devastating impact on the quality of life of patients but also on the healthcare system and the society. In particular, it will be focused on the current state and future perspectives in the area of innovation in ocular pharmacology, including treatments which have already demonstrated to generate improvements in patient outcomes that were previously unattainable, but also experimental products which would potentially represent disease modifying therapies. In this context, for instance manuscripts focused on advanced therapy medicinal products (ATMPs) are welcome; indeed, ATMPs, for example gene therapies, are changing the landscape of therapy for ocular diseases aiming to reverse and/or prevent blindness in patients with rare genetic disorders but also with chronic degenerative damages. As regard to products already on the market, evidence from real-world data will be acceptable, including commentaries about access to innovation.
This topic aims to look at innovative treatments but is not limited to the topic of advanced therapies. The Topic welcomes submissions of Original Research, Reviews, Clinical trials, Perspective, Policy Brief, Opinion articles that cover the following topics, but not limited to:
• Real-world data related to the use of products for ocular diseases recognized as real innovation already available in clinical practice (including gene therapies, novel formulations, biologics etc.);
• Access to innovation in specific national contexts (reimbursement, risk-sharing agreements, cost);
• Investigation on potential innovative pharmacological treatments for unmet medical needs (retinal dystrophies, glaucoma, diabetic retinopathy, age related macular degeneration);
• Innovative ocular drug delivery systems.